Measuring Vasculitis with Numbers: Outcome Scores

Author(s): Ezgi Deniz Batu, Seza Ozen*

Journal Name: Current Rheumatology Reviews

Volume 16 , Issue 1 , 2020

Become EABM
Become Reviewer

Abstract:

Primary Systemic Vasculitides (PSV) are a heterogeneous group of diseases. Outcome scores are important to evaluate vasculitis patients in a more structured and standard way and these help physicians to predict patients with poor prognosis or high risk of relapse. Furthermore, we need reliable outcome measures for clinical trials. There are a number of vasculitis outcome scores available in the clinical practice with different strengths and limitations. These are mainly measures of disease activity, disease damage, response to treatment and quality of life. Birmingham Vasculitis Activity Score (BVAS) and its pediatric version aim to evaluate a wide scope of PSV. On the other hand, some outcome studies have focused on a single vasculitis type since the whole group includes different diseases with heterogeneous clinical features.

The aim of this review is to provide an overview on outcome measures currently being used in the evaluation of patients with PSV. We mainly focus on immunoglobulin A vasculitis/Henochschönlein purpura, Kawasaki disease, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, polyarteritis nodosa, Takayasu arteritis and Behçet’s disease.

Keywords: Systemic vasculitis, outcome score, prognosis, BVAS, PVAS, FFS.

[1]
Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002; 360(9341): 1197-202.
[http://dx.doi.org/10.1016/S0140-6736(02)11279-7] [PMID: 12401245]
[2]
Watts RA, Mooney J, Skinner J, Scott DG, Macgregor AJ. The contrasting epidemiology of granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis. Rheumatology (Oxford) 2012; 51(5): 926-31.
[http://dx.doi.org/10.1093/rheumatology/ker454] [PMID: 22258386]
[3]
Batu ED, Ozen S. Pediatric vasculitis. Curr Rheumatol Rep 2012; 14(2): 121-9.
[http://dx.doi.org/10.1007/s11926-011-0232-4] [PMID: 22231274]
[4]
Watts RA, Lane S, Scott DG. What is known about the epidemiology of the vasculitides? Best Pract Res Clin Rheumatol 2005; 19(2): 191-207.
[http://dx.doi.org/10.1016/j.berh.2004.11.006] [PMID: 15857791]
[5]
Sag E, Batu ED, Ozen S. Childhood systemic vasculitis. Best Pract Res Clin Rheumatol 2017; 31(4): 558-75.
[http://dx.doi.org/10.1016/j.berh.2017.11.009] [PMID: 29773273]
[6]
Batu ED, Sarı A, Erden A, et al. Comparing immunoglobulin A vasculitis (Henoch-Schönlein purpura) in children and adults: a single-centre study from Turkey. Scand J Rheumatol 2018; 47(6): 481-6.
[http://dx.doi.org/10.1080/03009742.2018.1448111] [PMID: 29912602]
[7]
Garen T, Lerang K, Hoffmann-Vold AM, et al. Mortality and causes of death across the systemic connective tissue diseases and the primary systemic vasculitides. Rheumatology 2019; 58(2): 313-20.
[8]
Ozen S, Batu ED. Vasculitis pathogenesis: Can we talk about precision medicine? Front Immunol 2018; 9: 1892.
[http://dx.doi.org/10.3389/fimmu.2018.01892] [PMID: 30154798]
[9]
Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009; 68(12): 1827-32.
[http://dx.doi.org/10.1136/ard.2008.101279] [PMID: 19054820]
[10]
Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87(11): 671-8.
[PMID: 7820541]
[11]
Suppiah R, Mukhtyar C, Flossmann O, et al. A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology (Oxford) 2011; 50(5): 899-905.
[http://dx.doi.org/10.1093/rheumatology/keq400] [PMID: 21156667]
[12]
Bai YH, Li ZY, Chang DY, Chen M, Kallenberg CG, Zhao MH. The BVAS is an independent predictor of cardiovascular events and cardiovascular disease-related mortality in patients with ANCA-associated vasculitis: A study of 504 cases in a single Chinese center. Semin Arthritis Rheum 2018; 47(4): 524-9.
[http://dx.doi.org/10.1016/j.semarthrit.2017.07.004] [PMID: 28917713]
[13]
Itabashi M, Takei T, Morito T, et al. Estimation of BVAS in patients with microscopic polyangiitis in Japan. Clin Rheumatol 2011; 30(11): 1499-505.
[http://dx.doi.org/10.1007/s10067-011-1838-7] [PMID: 21887487]
[14]
Yoo J, Kim HJ, Jung SM, Song JJ, Park YB, Lee SW. Birmingham vasculitis activity score of more than 9.5 at diagnosis is an independent predictor of refractory disease in granulomatosis with polyangiitis. Int J Rheum Dis 2017; 20(10): 1593-605.
[http://dx.doi.org/10.1111/1756-185X.13144] [PMID: 28766857]
[15]
Demirkaya E, Ozen S, Pistorio A, et al. Paediatric Rheumatology International Trials Organization (PRINTO). Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides. Clin Exp Rheumatol 2012; 30(1)(Suppl. 70): S162-8.
[PMID: 22640658]
[16]
Dolezalova P, Price-Kuehne FE, Özen S, et al. Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Ann Rheum Dis 2013; 72(10): 1628-33.
[http://dx.doi.org/10.1136/annrheumdis-2012-202111] [PMID: 23100606]
[17]
Guillevin L, Lhote F, Amouroux J, Gherardi R, Callard P, Casassus P. Antineutrophil cytoplasmic antibodies, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg-Strauss syndrome: indications for the classification of vasculitides of the polyarteritis Nodosa Group. Br J Rheumatol 1996; 35(10): 958-64.
[http://dx.doi.org/10.1093/rheumatology/35.10.958] [PMID: 8883433]
[18]
Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P. French Vasculitis Study Group (FVSG). The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011; 90(1): 19-27.
[http://dx.doi.org/10.1097/MD.0b013e318205a4c6] [PMID: 21200183]
[19]
Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997; 40(2): 371-80.
[http://dx.doi.org/10.1002/art.1780400222] [PMID: 9041949]
[20]
Mohammad AJ, Bakoush O, Sturfelt G, Segelmark M. The extent and pattern of organ damage in small vessel vasculitis measured by the Vasculitis Damage Index (VDI). Scand J Rheumatol 2009; 38(4): 268-75.
[http://dx.doi.org/10.1080/03009740802668554] [PMID: 19296401]
[21]
Omma A, Erer B, Karadag O, et al. Remarkable damage along with poor quality of life in Takayasu arteritis: cross-sectional results of a long-term followed-up multicentre cohort Clin Exp Rheumatol 2017; 35 Suppl 103(1): 77-82
[22]
Seo P, Min YI, Holbrook JT, et al. WGET Research Group.Damage caused by Wegener’s granulomatosis and its treatment: prospective data from the Wegener’s Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005; 52(7): 2168-78.
[http://dx.doi.org/10.1002/art.21117] [PMID: 15986348]
[23]
Dolezalova P, Wilkinson N, Brogan PA, et al. SAT0286 paediatric vasculitis damage index: A new tool for standardised disease assessment. Ann Rheum Dis 2014; 73(Suppl. 2): 696-7.
[http://dx.doi.org/10.1136/annrheumdis-2014-eular.5893] [PMID: ]
[24]
Eleftheriou D, Varnier G, Dolezalova P, McMahon AM, Al-Obaidi M, Brogan PA. Takayasu arteritis in childhood: retrospective experience from a tertiary referral centre in the United Kingdom. Arthritis Res Ther 2015; 17: 36.
[http://dx.doi.org/10.1186/s13075-015-0545-1] [PMID: 25879697]
[25]
Morishita KA, Moorthy LN, Lubieniecka JM, et al. ARChiVe investigators network within the PedVas Initiative. Early outcomes in children with antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 2017; 69(7): 1470-9.
[http://dx.doi.org/10.1002/art.40112] [PMID: 28371513]
[26]
Lamprecht P, Moosig F, Gause A, et al. Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis. Ann Rheum Dis 2001; 60(4): 385-90.
[http://dx.doi.org/10.1136/ard.60.4.385] [PMID: 11247870]
[27]
Schmidt WA. Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep 2004; 6(3): 203-11.
[http://dx.doi.org/10.1007/s11926-004-0069-1] [PMID: 15134599]
[28]
Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suárez LF, van der Woude FJ. European Vasculitis Study Group. Treatment of refractory Wegener’s granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004; 65(4): 1440-8.
[http://dx.doi.org/10.1111/j.1523-1755.2004.00534.x] [PMID: 15086487]
[29]
de Groot K, Gross WL, Herlyn K, Reinhold-Keller E. Development and validation of a disease extent index for Wegener’s granulomatosis. Clin Nephrol 2001; 55(1): 31-8.
[PMID: 11200865]
[30]
Cella D, Yount S, Rothrock N, et al. PROMIS Cooperative Group.The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 2007; 45(5)(Suppl. 1): S3-S11.
[http://dx.doi.org/10.1097/01.mlr.0000258615.42478.55] [PMID: 17443116]
[31]
Robson JC, Tomasson G, Milman N, et al. OMERACT endorsement of patient-reported outcome instruments in antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol 2017; 44(10): 1529-35.
[http://dx.doi.org/10.3899/jrheum.161139] [PMID: 28864650]
[32]
Robson JC, Dawson J, Doll H, et al. Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. Ann Rheum Dis 2018; 77(8): 1157-64.
[http://dx.doi.org/10.1136/annrheumdis-2017-212713] [PMID: 29695498]
[33]
Fidanci BE, Demirkaya E, Acikel C, et al. FMF arthritis vasculitis and orphan disease research in paediatric rheumatology. The invisible part of the iceberg: qualitative aspects of childhood vasculitis. Clin Exp Rheumatol 2014; 32(3)(Suppl. 82): S122-7.
[PMID: 24021608]
[34]
Eleftheriou D, Batu ED, Ozen S, Brogan PA. Vasculitis in children. Nephrol Dial Transplant 2015; 30(Suppl. 1): i94-i103.
[PMID: 25550447]
[35]
Byun JW, Song HJ, Kim L, Shin JH, Choi GS. Predictive factors of relapse in adult with Henoch-Schönlein purpura. Am J Dermatopathol 2012; 34(2): 139-44.
[http://dx.doi.org/10.1097/DAD.0b013e3182157f90] [PMID: 22441366]
[36]
Prais D, Amir J, Nussinovitch M. Recurrent Henoch-Schönlein purpura in children. J Clin Rheumatol 2007; 13(1): 25-8.
[http://dx.doi.org/10.1097/01.rhu.0000255692.46165.19] [PMID: 17278945]
[37]
Rigante D, Candelli M, Federico G, Bartolozzi F, Porri MG, Stabile A. Predictive factors of renal involvement or relapsing disease in children with Henoch-Schönlein purpura. Rheumatol Int 2005; 25(1): 45-8.
[http://dx.doi.org/10.1007/s00296-004-0452-2] [PMID: 15007622]
[38]
Shin JI, Park JM, Shin YH, Hwang DH, Kim JH, Lee JS. Predictive factors for nephritis, relapse, and significant proteinuria in childhood Henoch-Schönlein purpura. Scand J Rheumatol 2006; 35(1): 56-60.
[http://dx.doi.org/10.1080/03009740510026841] [PMID: 16467044]
[39]
Calvo-Río V, Hernández JL, Ortiz-Sanjuán F, et al. Relapses in patients with Henoch-Schönlein purpura: Analysis of 417 patients from a single center. Medicine (Baltimore) 2016; 95(28)e4217
[http://dx.doi.org/10.1097/MD.0000000000004217] [PMID: 27428226]
[40]
Sanders JT, Wyatt RJ. IgA nephropathy and Henoch-Schönlein purpura nephritis. Curr Opin Pediatr 2008; 20(2): 163-70.
[http://dx.doi.org/10.1097/MOP.0b013e3282f4308b] [PMID: 18332712]
[41]
Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006; 149(2): 237-40.
[http://dx.doi.org/10.1016/j.jpeds.2006.03.050] [PMID: 16887442]
[42]
Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006; 113(22): 2606-12.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.105.592865] [PMID: 16735679]
[43]
Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007; 166(2): 131-7.
[http://dx.doi.org/10.1007/s00431-006-0223-z] [PMID: 16896641]
[44]
Sleeper LA, Minich LL, McCrindle BM, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance J Pediatr 2011; 158(5): 831-835: e833
[45]
Kanamitsu K, Kakimoto H, Shimada A, et al. Verification of risk scores to predict i.v. immunoglobulin resistance in incomplete Kawasaki disease. Pediatr Int (Roma) 2016; 58(2): 146-51.
[http://dx.doi.org/10.1111/ped.12755] [PMID: 26190225]
[46]
Kawai R, Nomura O, Tomobe Y, et al. Retrospective observational study indicates that the paediatric assessment triangle may suggest the severity of Kawasaki disease. Acta Paediatr 2018; 107(6): 1049-54.
[http://dx.doi.org/10.1111/apa.14249] [PMID: 29385646]
[47]
Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996; 75(1): 17-28.
[http://dx.doi.org/10.1097/00005792-199601000-00003] [PMID: 8569467]
[48]
Gayraud M, Guillevin L, le Toumelin P, et al. French Vasculitis Study Group. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44(3): 666-75.
[http://dx.doi.org/10.1002/1529-0131(200103)44:3<666:AID-ANR116>3.0.CO;2-A] [PMID: 11263782]
[49]
Oh YJ, Ahn SS, Park ES, et al. Birmingham vasculitis activity score at diagnosis is a significant predictor of relapse of polyarteritis nodosa. Rheumatol Int 2017; 37(5): 685-94.
[http://dx.doi.org/10.1007/s00296-017-3706-5] [PMID: 28341881]
[50]
Abe Y, Tada K, Yamaji K, Takasaki Y, Tamura N. Association of five-factor score with the mortality in Japanese patients with polyarteritis nodosa. Mod Rheumatol 2018; 28(2): 308-12.
[http://dx.doi.org/10.1080/14397595.2017.1337265] [PMID: 28648103]
[51]
Erden A, Batu ED, Sönmez HE, et al. Comparing polyarteritis nodosa in children and adults: a single center study. Int J Rheum Dis 2017; 20(8): 1016-22.
[http://dx.doi.org/10.1111/1756-185X.13120] [PMID: 28626961]
[52]
Merlin E, Mouy R, Pereira B, et al. Long-term outcome of children with pediatric-onset cutaneous and visceral polyarteritis nodosa. Joint Bone Spine 2015; 82(4): 251-7.
[http://dx.doi.org/10.1016/j.jbspin.2015.01.007] [PMID: 25887252]
[53]
Eleftheriou D, Dillon MJ, Tullus K, et al. Systemic polyarteritis nodosa in the young: a single-center experience over thirty-two years. Arthritis Rheum 2013; 65(9): 2476-85.
[http://dx.doi.org/10.1002/art.38024] [PMID: 23754739]
[54]
Oh YJ, Ahn SS, Park ES, et al. Chest and renal involvements, Birmingham vascular activity score more than 13.5 and five factor score (1996) more than 1 at diagnosis are significant predictors of relapse of microscopic polyangiitis Clin Exp Rheumatol 2017; 35 Suppl 103(1): 47-54.
[55]
Mun CH, Yoo J, Jung SM, Song JJ, Park YB, Lee SW. The initial predictors of death in 153 patients with ANCA-associated vasculitis in a single Korean centre. Clin Exp Rheumatol 2018; 36(2)(Suppl. 111): 65-72.
[PMID: 29465370]
[56]
Merkel PA, Cuthbertson DD, Hellmich B, et al. Vasculitis Clinical Research Consortium.Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Ann Rheum Dis 2009; 68(1): 103-6.
[http://dx.doi.org/10.1136/ard.2008.097758] [PMID: 18664546]
[57]
Morishita K, Li SC, Muscal E, et al. ARChiVe Investigators Network. Assessing the performance of the Birmingham Vasculitis Activity Score at diagnosis for children with antineutrophil cytoplasmic antibody-associated vasculitis in A Registry for Childhood Vasculitis (ARChiVe). J Rheumatol 2012; 39(5): 1088-94.
[http://dx.doi.org/10.3899/jrheum.111030] [PMID: 22337238]
[58]
Stone JH, Hoffman GS, Merkel PA, et al. International Network for the Study of the Systemic Vasculitides (INSSYS). A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum 2001; 44(4): 912-20.
[http://dx.doi.org/10.1002/1529-0131(200104)44:4<912:AID-ANR148>3.0.CO;2-5] [PMID: 11318006]
[59]
Kucuk H, Varan O, Goker B, et al. Serum ferritin as an activity marker for granulamotosis with polyangiitis. Ren Fail 2017; 39(1): 566-9.
[http://dx.doi.org/10.1080/0886022X.2017.1349675] [PMID: 28741986]
[60]
Perez MO, Oliveira RM, Levy-Neto M, Caparbo VF, Pereira RMR. Serum 25-hydroxyvitamin D levels in patients with Granulomatosis with Polyangiitis: association with respiratory infection. Clinics (São Paulo) 2017; 72(12): 723-8.
[http://dx.doi.org/10.6061/clinics/2017(12)02] [PMID: 29319717]
[61]
Thai LH, Charles P, Resche-Rigon M, Desseaux K, Guillevin L. Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis (Wegener’s) relapses? Results of a retrospective study on 126 patients. Autoimmun Rev 2014; 13(3): 313-8.
[http://dx.doi.org/10.1016/j.autrev.2013.11.003] [PMID: 24225075]
[62]
Tomasson G, Davis JC, Hoffman GS, et al. Brief report: The value of a patient global assessment of disease activity in granulomatosis with polyangiitis (Wegener’s). Arthritis Rheumatol 2014; 66(2): 428-32.
[http://dx.doi.org/10.1002/art.38248] [PMID: 24504815]
[63]
Sivakumar MRMR, Bacon PA. The Indian perspective of Takayasu arteritis and development of a disease extent index (DEI.Tak) to assess Takayası arteritis. Rheumatology (Oxford) 2005; 44: iii6-7.
[http://dx.doi.org/10.1093/rheumatology/keh739]
[64]
Misra R, Danda D, Rajappa SM, et al. Indian Rheumatology Vasculitis (IRAVAS) group.Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford) 2013; 52(10): 1795-801.
[http://dx.doi.org/10.1093/rheumatology/ket128] [PMID: 23594468]
[65]
John RA, Keshava SN, Danda D. Correlating MRI with clinical evaluation in the assessment of disease activity of Takayasu’s arteritis. Int J Rheum Dis 2017; 20(7): 882-6.
[http://dx.doi.org/10.1111/1756-185X.12967] [PMID: 28736969]
[66]
Sinha D, Mondal S, Nag A, Ghosh A. Development of a colour Doppler ultrasound scoring system in patients of Takayasu’s arteritis and its correlation with clinical activity score (ITAS 2010). Rheumatology (Oxford) 2013; 52(12): 2196-202.
[http://dx.doi.org/10.1093/rheumatology/ket289] [PMID: 24014648]
[67]
Tezuka D, Haraguchi G, Ishihara T, et al. Role of FDG PET-CT in Takayasu arteritis: sensitive detection of recurrences. JACC Cardiovasc Imaging 2012; 5(4): 422-9.
[http://dx.doi.org/10.1016/j.jcmg.2012.01.013] [PMID: 22498333]
[68]
Alibaz-Oner F, Aydin SZ, Akar S, et al. Assessment of patients with takayasu arteritis in routine practice with indian takayasu clinical activity score. J Rheumatol 2015; 42(8): 1443-7.
[http://dx.doi.org/10.3899/jrheum.140817] [PMID: 26136490]
[69]
Goel R, Danda D, Joseph G, et al. Long-term outcome of 251 patients with Takayasu arteritis on combination immunosuppressant therapy: Single centre experience from a large tertiary care teaching hospital in Southern India. Semin Arthritis Rheum 2018; 47(5): 718-26.
[http://dx.doi.org/10.1016/j.semarthrit.2017.09.014] [PMID: 29096935]
[70]
Aeschlimann FA, Eng SWM, Sheikh S, et al. Childhood Takayasu arteritis: disease course and response to therapy. Arthritis Res Ther 2017; 19(1): 255.
[http://dx.doi.org/10.1186/s13075-017-1452-4] [PMID: 29166923]
[71]
Feng Y, Tang X, Liu M, Zhou J, Zhao X, Li Q. Clinical study of children with Takayasu arteritis: a retrospective study from a single center in China. Pediatr Rheumatol Online J 2017; 15(1): 29.
[http://dx.doi.org/10.1186/s12969-017-0164-2] [PMID: 28416004]
[72]
Sreih AG, Alibaz-Oner F, Kermani TA, et al. Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. J Rheumatol 2017; 44(12): 1933-7.
[http://dx.doi.org/10.3899/jrheum.161467] [PMID: 28864646]
[73]
Davatchi FAM, Shahram F, Tebbi M, Chams C, Chams H. Iran Behcet’s disease dynamic activity measure. Abstracts of the XIIth European congress of rheumatology Hungrian Rheumatol 32. 134
[74]
Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 1999; 38(8): 728-33.
[http://dx.doi.org/10.1093/rheumatology/38.8.728] [PMID: 10501420]
[75]
Shahram F, Khabbazi A, Nadji A, Ziaie N, Banihashemi AT, Davatchi F. Comparison of existing disease activity indices in the follow-up of patients with Behçet’s disease. Mod Rheumatol 2009; 19(5): 536-41.
[http://dx.doi.org/10.3109/s10165-009-0191-z] [PMID: 19590934]
[76]
Batu ED, Sonmez HE, Sozeri B, et al. The performance of different classification criteria in paediatric Behcet’s disease. Clin Exp Rheumatol 2017; 35(6)(Suppl. 108): 119-23.
[77]
Hatemi G, Meara A, Ozguler Y, et al. Developing a Core Set of Outcome Measures for Behçet Disease: Report from OMERACT 2016. J Rheumatol 2017; 44(11): 1750-3.
[http://dx.doi.org/10.3899/jrheum.161352] [PMID: 28365574]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2020
Page: [21 - 28]
Pages: 8
DOI: 10.2174/1573397115666191126093927
Price: $65

Article Metrics

PDF: 20
HTML: 3